10x Genomics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M | $490.5M |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M |
| Operating income | -$61.0M | -$194.6M | -$265.3M | -$167.9M | -$52.3M |
| Operating expenses | $504.9M | $609.0M | $674.6M | $564.0M | $468.7M |
| Cost of revenue | $198.9M | $196.3M | $209.4M | $120.4M | $74.1M |
| Cash from operations | $136.1M | $6.7M | -$15.2M | -$33.6M | -$21.4M |
| Capital expenditure | $5.9M | $12.4M | $48.6M | $131.7M | $101.3M |
| Free cash flow | $130.1M | -$5.7M | -$63.8M | -$165.3M | -$122.7M |
| Impairments | $2.1M | $3.1M | $9.8M | $0 | $0 |
| Total assets | $1.0B | $918.6M | $965.1M | $1.0B | $1.0B |
| Total liabilities | $245.0M | $208.5M | $224.1M | $223.2M | $201.3M |
Shares outstanding 127.0M · Free float 84.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.